DaunorubicinAntibiotics, AntineoplasticNaphthacenesCytarabineDoxorubicinAntineoplastic AgentsP-GlycoproteinIdarubicinDrug Resistance, MultipleDrug Resistance, NeoplasmAnthracyclinesDrug ResistanceLeukemia, Myeloid, AcuteLeukemia P388VerapamilThioguanineCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsTumor Cells, CulturedApoptosisVincristineMitoxantroneEtoposideDrug Screening Assays, AntitumorRazoxaneCyclosporinsCarcinoma, Ehrlich TumorDrug SynergismCell SurvivalLeukemia, MyeloidRemission InductionAclarubicinCisplatinAntineoplastic Agents, PhytogenicStreptomycesDose-Response Relationship, DrugHL-60 CellsLiposomesMultidrug Resistance-Associated ProteinsAsparaginaseGenes, MDRK562 CellsAntimetabolites, AntineoplasticNeoplasmsDrug Delivery SystemsDrug CarriersRhodamine 123PaclitaxelLeukemiaPyrazolonesAnthraquinonesBenzylisoquinolinesDrug AgonismConsolidation Chemotherapy6-MercaptopurineVinblastineMethotrexateLeukemia L1210Inhibitory Concentration 50ATP-Binding Cassette TransportersLeukemia, ExperimentalAntineoplastic Agents, AlkylatingFluorouracilCell ProliferationAcute DiseaseDrug Administration SchedulePrecursor Cell Lymphoblastic Leukemia-LymphomaCell DivisionNeoplasm ProteinsFlow CytometryVault Ribonucleoprotein ParticlesLung NeoplasmsTreatment OutcomeCyclophosphamideNanomedicineXenograft Model Antitumor AssaysDrug InteractionsTopoisomerase II Inhibitors